CB -- BIOrest LABR-312, an IV anti-inflammatory drug, reduced the rates of late loss in diabetic patients and those with high counts of monocyte, and exhibited no safety concerns or signs of overall in-stent lumen loss in stenosis patients, according to the results of the late-breaking BLAST trial presented Sept. 24 at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting.
